Recombinant Human Serine/threonine-protein kinase PLK1 (PLK1), partial
Description
Purity > 90% as determined by SDS-PAGE. MW: 70.3kDa. Extracellular Domain: 1-603aa. N-terminal 6xHis-tagged. Homo sapiens (Human). Activated by phosphorylation of Thr-210 by AURKA; phosphorylation by AURKA is enhanced by BORA. Once activated, activity is stimulated by binding target proteins. Binding of target proteins has no effect on the non-activated kinase. Several inhibitors targeting PLKs are currently in development and are under investigation in a growing number of clinical trials, such as BI 2536, an ATP-competitive PLK1 inhibitor or BI 6727, a dihydropteridinone that specifically inhibits the catalytic activity of PLK1.